Batimastat BiodivYsio stent deal

British Biotech (LSE:BBG; BBIOY) and BioCompatibles (LSE:BII) will develop vascular stents loaded with batimastat (BB-94), BBG's first generation matrix metalloproteinase inhibitor. The batimastat-loaded stent is aimed at reducing restenosis in patients who have undergone coronary angioplasty, thus improving the stent's performance. BBG will fund clinical costs, and will receive milestones and royalties on sales. BII will run the clinical trials and be responsible for worldwide regulatory filings and commercialization. The batimastat BiodivYsio stent is expected to enter the clinic mid-year. ...